Author Archives: Bruno Quinney

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

Heart monitor
#Biotech #Financing #Heart failure #Italy

NanoPhoria builds on record-breaking financing round

NanoPhoria Bioscience has announced the second closing of its series A financing round, including a €15 million equity investment from the European Innovation Council (EIC) Fund. The company recently received the largest ever Series A financing round in Italian biotech history, Alongside the EIC, NanoPhoria also received… Read More

#Business & Investment #News

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News

Vaccine
#Biotech #Cancer vaccines #Infinitopes

Infinitopes secures funding to develop cancer vaccine 

Biotechnology company Infinitopes has raised $35.1 million in a seed financing round to accelerate the development of a precision cancer vaccine.  The latest finance round was co-led by Octopus Ventures and new investor Amplify Bio, with further participation from new investor Macmillan Cancer Support and existing investors Cancer Research… Read More

#Business & Investment #News

Node structures in the central nervous system
#Alzheimer's #Biotech #CNS #Insilico Medicine #Parkinson's

Insilico and Hygtia Therapeutics partner on CNS disease drug 

Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but… Read More

#Business & Investment #News

Doctor points at child's brain scan
#Brain #Italy

Brain health pharma company appoints new CEO 

Sergio Marullo di Condojanni has been appointed Chief Executive Officer of Italian pharma company Angelini Pharma.  Di Condojanni has served as CEO of Angelini Industries since 2020 and will maintain that role while assuming leadership of the pharmaceutical division to drive the company’s strategy implementation, leveraging extensive executive, governance, and financial expertise.  Angelini Pharma,… Read More

#News

Female medical researcher
#BioXcel Therapeutics #Bipolar #FDA #Schizophrenia

sNDA application submitted for agitation drug 

Biopharmaceutical company BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for agitation treatment Igalmi.  Igalmi (dexmedetomidine) is a prescription medicine used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I and II in adults.   In April 2022, Igalmi was… Read More

#News #Regulatory

#AI #Clinical trial #Drug discovery #Parse Biosciences

Life science partnership to improve AI-driven drug discovery  

Life sciences company Parse Biosciences has partnered with research institute Graph Therapeutics to create what it says is one of the largest and most comprehensive immune cell perturbation atlases.  The collaboration will leverage Graph’s lab-in-the-loop platform with Parse’s GigLab to profile hundreds of millions of cells from patients with immune diseases… Read More

#Business & Investment #News

Non-small cell lung cancer
#Clinical trial #Gut microbiome #Non-small cell lung cancer (NSCLC)

First patient randomised in NSCLC Phase II trial 

The first patient has been randomised in a Phase II trial evaluating an oral microbiome therapy in combination with Cemiplimab to treat patients with advanced non-small cell lung cancer (NSCLC).  Maat033, an oral microbiome developed by biotechnology company MaaT Pharma, is being studied as a treatment in combination with Cemiplimab in enhancing disease… Read More

#News

Gene therapy
#FDA #Gene therapy #Orphan drugs

FDA grants orphan drug designation to MMA treatment 

The US Food and Drug Administration (FDA) has granted orphan drug designation to a treatment for methylmalonic acidaemia (MMA).  GENE202, developed by biotechnology company Genespire, is an in vivo off-the-shelf gene therapy which harnesses the company’s Immune Shielded Lentiviral Vector (ISLV) platform to treat paediatric patients affected by genetic diseases. Read More

#News #Regulatory

Melanoma or skin cancer
#Clinical trial #Melanoma #Merck #Moderna

Combination therapy could slash melanoma mortality risk 

Merck and Moderna have announced encouraging five-year data for a therapy treating patients with high-risk melanoma.  The Phase IIb trial of intismeran autogene, an investigational mRNA-based individualised neoantigen therapy (INT), reduced the risk of high-risk melanoma recurrence or death by 49% when combined with Keytruda (pembrolizumab).  The combination… Read More

#News

Conference microphone
#Cell and gene therapy #ELRIG #UK

ELRIG announces keynote speakers for CGT conference 

ELRIG has announced Dr Stephen Ward and Dr Annarita Miccio as keynote speakers for its Cell and Gene Therapy event in March.  The not-for-profit organisation aims to bring together leading scientists, economists and patient advocates to explore breakthroughs shaping the future of medicine.   The programme, focussing on… Read More

#News

#Biology #Biotech #Canada

VoxCell appoints Graham Craig as COO 

Canadian biotechnology company VoxCell has appointed Graham Craig as Chief Commercial Officer (COO).  Craig joins VoxCell from clinical-stage biotechnology company AbCellera with experience in commercialisation and strategic partnerships across the pharmaceutical and biotech sectors. Craig will lead VoxCell’s commercial strategy, including global business development, strategic partnerships, and go-to-market execution as the industry accelerates adoption of… Read More

#News

Concussion brain scan
#Clinical trial #Concussion #Oxeia Biopharmaceuticals

Oxeia advances potential first FDA-approved concussion drug 

Biotech Oxeia Biopharmaceuticals is advancing a potential first FDA-approved concussion treatment into Phase IIb clinical testing.  OXE103, a therapy for persistent concussion symptoms, demonstrated an 85% responder rate in Phase IIa clinical testing and will be evaluated in Phase IIb trial.  Between 1.4 and 4.2 million people… Read More

#News

#Drug discovery #Genomics #OutSee

OutSee raises £2.5m and partners with o2h discovery 

Genomic and drug discovery company OutSee has closed a £2.5 million ($3.4 million) seed funding round and partnered with contract research organisation o2h discovery to develop a lead drug target candidate.  The partnership aims to launch a collaborative drug discovery programme for OutSee’s lead target candidate, identified through the company’s genomic target discovery… Read More

#Business & Investment #News